Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Stacey E. Chin"'
Autor:
Stacey E. Chin, Christina Schindler, Lisa Vinall, Roger B. Dodd, Lisa Bamber, Sandrine Legg, Anna Sigurdardottir, D. Gareth Rees, Tim I. M. Malcolm, Samantha J. Spratley, Cecilia Granéli, Jonathan Sumner, Natalie J. Tigue
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract Chemical inducer of dimerization (CID) modules can be used effectively as molecular switches to control biological processes, and thus there is significant interest within the synthetic biology community in identifying novel CID systems. To
Externí odkaz:
https://doaj.org/article/1c4fb2f0a98149f7bb083c8fbced398e
Autor:
Jessica S. Ebo, Janet C. Saunders, Paul W. A. Devine, Alice M. Gordon, Amy S. Warwick, Bob Schiffrin, Stacey E. Chin, Elizabeth England, James D. Button, Christopher Lloyd, Nicholas J. Bond, Alison E. Ashcroft, Sheena E. Radford, David C. Lowe, David J. Brockwell
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Protein aggregation remains a significant challenge for manufacturing of protein biopharmaceuticals. Here, the authors demonstrate the use of directed evolution and an assay for in vivo innate protein aggregation-propensity to generate aggregation-re
Externí odkaz:
https://doaj.org/article/7cd4d27ccee2435a841e247a296e334c
Autor:
Paul W. A. Devine, Elizabeth England, Nicholas J. Bond, David C. Lowe, Amy S. Warwick, James Button, Sheena E. Radford, Janet C. Saunders, Bob Schiffrin, Alison E. Ashcroft, Alice M. Gordon, Chris Lloyd, David J. Brockwell, Stacey E. Chin, Jessica S. Ebo
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Nature Communications
Nature Communications
Protein biopharmaceuticals are highly successful, but their utility is compromised by their propensity to aggregate during manufacture and storage. As aggregation can be triggered by non-native states, whose population is not necessarily related to t
Publikováno v:
Journal of immunological methods. 416
Anti-idiotype antibodies against a therapeutic antibody are key reagents for the development of immunogenicity and pharmacokinetic (PK) assays during pre-clinical and clinical development. Here we have used a combination of phage and ribosome display